Company continues to lead the dental laser
industry with 302 issued and 31 pending patents
LAKE
FOREST, Calif., July 25,
2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:
BIOL), the global leader in dental lasers, announced today that the
company has received five new United
States patents and seven new foreign patents in the last
12 months.
In June, the company received notice from the Korean
Intellectual Property Office of the Decision to Grant, "KR #2412063
titled Pre-Initiated Optical Fibers for Medical
Applications," an important addition to BIOLASE's Korean IP
portfolio. Also, the Canadian Intellectual Property Office (CIPO)
granted, #2,935,691 titled Dual Wavelength Laser Treatment
Device.
Two additional recent patents are US #11,250,941 titled
Dental Laser Interface System and Method issued on
Feb. 15, 2022, issued in the U.S. and
BR112015008998-4, Handpiece Assembly for Laser Treatment
Device issued in Brazil
on Feb. 8, 2022.
BIOLASE maintains an industry-leading portfolio of
intellectual property ("IP") with 302 issued and 31 pending
applications.
"BIOLASE's proprietary laser products represent decades of
innovative research and incorporate many patented and
patent-pending technologies specifically designed and tested to
provide biologically and clinically superior performance with a
more comfortable patient experience and faster recovery times,"
commented BIOLASE Vice President of Innovation and Business
Development, William Brown,
Jr.
"The new patents are all related to the flagship Waterlase laser
systems and market-leading Epic diode technologies, and expand
the protection of BIOLASE's key IP well into the future," said
John Beaver, President and Chief
Executive Officer of BIOLASE.
About BIOLASE
BIOLASE is a medical device company that develops,
manufactures, markets, and sells laser systems in dentistry and
medicine. BIOLASE's products advance the practice of dentistry and
medicine for patients and healthcare professionals. BIOLASE's
innovative products provide cutting-edge technology at competitive
prices to deliver superior results for dentists and patients.
BIOLASE's principal products are revolutionary dental laser systems
that perform a broad range of dental procedures, including cosmetic
and complex surgical applications. BIOLASE has sold over
43,300 laser systems to date in over 80 countries around the world.
Laser products under development address BIOLASE's core dental
market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online
at www.biolase.com, Facebook at www.facebook.com/biolase,
Twitter at www.twitter.com/biolaseinc, Instagram
at www.instagram.com/waterlase_laserdentistry, and LinkedIn
at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties. Forward-looking
statements can be identified through the use of words such as may,"
"might," "will," "intend," "should," "could," "can," "would,"
"continue," "expect," "believe," "anticipate," "estimate,"
"predict," "outlook," "potential," "plan," "seek," and similar
expressions and variations or the negatives of these terms or other
comparable terminology. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect
BIOLASE's current expectations and speak only as of the date of
this release. Actual results may differ materially from BIOLASE's
current expectations depending upon a number of factors. These
factors include, among others, those risks and uncertainties that
are described in the "Risk Factors" section of BIOLASE's annual
report filed on Form 10-K filed with the Securities and Exchange
Commission. Except as required by law, BIOLASE does not undertake
any responsibility to revise or update any forward-looking
statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolase-expands-intellectual-property-portfolio-with-new-united-states-and-foreign-patents-301592167.html
SOURCE BIOLASE, Inc.